German Biotech: "Catching-Up Needed"

29 September 1996

Germany still has considerable ground to make up in biotechnology and genetic engineering, a symposium organized by the national chemistry industry, the VCI, which has a new biotechnology division, has heard.

Patricia Solaro, director of the North Rhine-Westphalia government initiative to promote biotechnology, said the main drawback was Germany's disadvantages compared with competitor countries in assessing and evaluating R&D results. Also, German scientists lack the backing of management expertise and risk capital.

She said the biotechnology world market would expand from about 10 billion Deutschemarks in 1990 to about 160 billion marks ($105.88 billion) in 2000. Agrochemicals account for the fastest growth, up from 4.8 billion marks in 1990 to 80 billion marks by 2000, followed by pharmaceuticals growing from 2.4 billion marks to 47.8 billion marks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight